Business Context and Reporting Period
Company: NorthView Acquisition Corp. (filing as NorthView Acquisition Corp., pending name change to Profusa, Inc. upon business combination).
Filing Type: Form 10-K (Annual Report).
Period: Fiscal year ended December 31, 2024.
Business Model: Special Purpose Acquisition Company (SPAC) formed to effect a business combination with Profusa, Inc., a healthcare innovation company. The company has no operating revenues and relies on interest income from a Trust Account and related party financing.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | Value |
|---|---|
| Net Loss | $(8,711,619) |
| Operating Costs | $1,351,038 |
| Interest Income (Trust Account) | $425,416 |
| Cash and Cash Equivalents | $16,204 |
| Trust Account Balance | $8,330,835 |
| Working Capital Deficit | $(12,254,024) |
| Convertible Promissory Note (Fair Value) | $8,908,052 |
| Warrant Liabilities (Fair Value) | $696,170 |
| Excise Tax Payable | $1,880,944 |
Material Changes vs. Prior Period
- Profitability: The company reported a net loss of $8.7 million in 2024, compared to a net income of $1.2 million in 2023. The loss was primarily driven by a $7.2 million increase in the fair value of the convertible promissory note and a $0.5 million increase in warrant liabilities.
- Trust Account: The Trust Account balance decreased from $10.9 million in 2023 to $8.3 million in 2024 due to shareholder redemptions ($3.2 million) and extension fees, partially offset by interest income.
- Debt: The fair value of the convertible promissory note increased significantly from $0.9 million in 2023 to $8.9 million in 2024, reflecting changes in valuation inputs and additional borrowings ($0.8 million principal).
- Listing Status: The company was delisted from Nasdaq on December 27, 2024, due to failure to complete a business combination within 36 months of its IPO. Securities now trade on the OTC Pink market.
Guidance, Outlook, Risks, and Unusual Items
- Business Combination Status: A Merger Agreement with Profusa, Inc. remains in place but has been amended multiple times (Amendment No. 4 filed Feb 2025). The deadline to consummate the transaction has been extended to June 22, 2025.
- Going Concern: Management has determined that substantial doubt exists regarding the company's ability to continue as a going concern for the next twelve months if a business combination is not completed by June 22, 2025.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting as of December 31, 2024, specifically regarding the valuation of convertible notes and warrants, and the recording of expenses.
- Unusual Items:
- Excise Tax: A liability of $1.9 million is recorded for the 1% excise tax on stock repurchases (redemptions) under the Inflation Reduction Act.
- Redemptions: Significant shareholder redemptions occurred throughout 2024 and early 2025, reducing the Trust Account balance and the number of public shares outstanding.
- Financing: The company entered into a securities purchase agreement in February 2025 for up to $22.2 million in senior secured convertible notes to fund the transaction.
Investor Verification Checklist
- Transaction Viability: Verify the current status of the Merger Agreement with Profusa, Inc., specifically the satisfaction of the $15 million minimum cash condition and the status of the APAC Joint Venture milestone.
- Liquidity Runway: Confirm the sufficiency of the $16,204 cash balance and the $8.3 million Trust Account to meet obligations through the June 22, 2025 deadline, given the working capital deficit.
- Debt Valuation: Review the assumptions used to value the convertible promissory note at $8.9 million, as this non-cash liability significantly impacts the reported net loss.
- Internal Controls: Assess the remediation plan for the material weaknesses in internal controls identified in the 2024 audit.
- Delisting Impact: Evaluate the impact of trading on the OTC Pink market on liquidity and the ability to meet Nasdaq listing requirements for the post-combination entity.